Pilot Study Pancreatic and Ovarian Screening MR Imaging of Rapid With Motion Corrected T1, T2, and Advanced Diffusion Weighted Imaging for Patients With BRCA Mutation Who Undergo Screening Breast MRI
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Screening Breast MRI in Patients Who Are BRCA Mutation Carriers
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Enrollment
- 63
- Locations
- 1
- Primary Endpoint
- define optimized acquisition
- Status
- Active, not recruiting
- Last Updated
- 9 months ago
Overview
Brief Summary
The purpose of this study is to create a rapid scan of the pancreas and ovaries that could be used in the future to screen patients at risk for pancreatic or ovarian cancers. Currently, Magnetic Resonance Imaging (MRI) examinations of the pancreas and ovaries can last 30-45 minutes each. The investigators hope to create a rapid pancreatic and ovarian MRI evaluation that can be used as a screening tool that is completed in approximately 15 minutes. They will compare different tools available on modern MRI scanners to see which one reliably offers high quality images of the pancreas and ovaries.
Investigators
Eligibility Criteria
Inclusion Criteria
- •BRCA 1 or 2 mutation
- •Patients scheduled to undergo screening breast MRI with contrast
Exclusion Criteria
- •Patients with known breast cancer
- •Patients unable to complete their scheduled breast MRI
- •Patients with prior pancreatic surgery or cancers
- •Patients with prior ovarian cancer or surgery involving removal of one or both ovaries
- •Patients with prior abdominal or pelvic surgery
Outcomes
Primary Outcomes
define optimized acquisition
Time Frame: 1 year
The images will be evaluated qualitatively for image quality from 1 to 5 with 5 = not adequate and 1 = adequate image quality by two radiologists in consensus. If both radiologists give a score of 1, the sequence will be considered to be adequate in image quality. Quantitative measurements of SNR will be performed on the pancreatic head, body and tail, and ovarian tissue by region of interest (ROI) analysis. Final acquisition times and spatial resolution for each sequence will be recorded.